Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Trial of the Safety and Tolerability of IC51, an Inactivated Japanese Encephalitis Vaccine | Zendy

Erich Tauber | Zendy; Herwig Kollaritsch | Zendy; Frank von Sonnenburg | Zendy; Matthias Lademann | Zendy; Bernd Jilma | Zendy; Christa Firbas | Zendy; Tomáš Jelı́nek | Zendy; Charmagne Beckett | Zendy; Jürgen Knobloch | Zendy; William J. McBride | Zendy; Elisabeth Schuller | Zendy; A. Kaltenböck | Zendy; Wellington Sun | Zendy; Arthur Lyons | Zendy

Open Access

Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Trial of the Safety and Tolerability of IC51, an Inactivated Japanese Encephalitis Vaccine

Author(s) -

Erich Tauber,

Herwig Kollaritsch,

Frank von Sonnenburg,

Matthias Lademann,

Bernd Jilma,

Christa Firbas,

Tomáš Jelı́nek,

Charmagne Beckett,

Jürgen Knobloch,

William J. McBride,

Elisabeth Schuller,

A. Kaltenböck,

Wellington Sun,

Arthur Lyons

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/590116

Subject(s) - tolerability , medicine , placebo , adverse effect , randomized controlled trial , japanese encephalitis vaccine , encephalitis , japanese encephalitis , reactogenicity , immunogenicity , immunology , virology , pediatrics , virus , immune system , pathology , alternative medicine

Japanese encephalitis (JE) is the most important mosquito-borne viral encephalitis and has a high case fatality rate. It is caused by Japanese encephalitis virus. Improved vaccines are urgently needed for residents in countries of endemicity, travelers, and the military. The aim of the present trial was to evaluate the safety and tolerability of IC51, Intercell's Vero cell-derived, purified, inactivated JE vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research